EMA Greenlights Ronapreve & Regkirona For COVID-19 In EU

The European Commission is likely to act rapidly on the formal approval of coronavirus treatments casirivimab/imdevimab and regdanvimab.

COVID-19 graphic
Treatments for COVID-19 are still needed despite the increase in vaccinations • Source: Shutterstock

The EU is likely to have its first two anti-COVID-19 monoclonal antibody products available shortly, after the European Medicines Agency gave the green light to Regeneron Pharmaceuticals, Inc./Roche’s Ronapreve and Celltrion, Inc.’s Regkirona.

On 11 November the EMA announced that its human drugs committee, the CHMP, had recommended authorizing Ronapreve (casirivimab/imdevimab) for treating...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography